Eli Lilly CEO vows not to raise insulin prices again, while Novo Nordisk and Sanofi hedge

He was the only executive to do so before a Senate Health Committee hearing that also included the CEOs of Novo Nordisk and Sanofi.

from Health and Science https://ift.tt/xzHCXaE
https://ift.tt/Id2i0bJ
https://ift.tt/pHGSNPn